AAAAAA
Results:
1-22
|
Results: 22
Authors:
Wirt, DP
Giles, FJ
Oken, MM
Solal-Celigny, P
Beck, JR
Citation: Dp. Wirt et al., Cost-effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma, LEUK LYMPH, 40(5-6), 2001, pp. 565-579
Authors:
Wiernik, PH
Leong, T
Oken, MM
Neiman, RS
Habermann, TM
Bennett, JM
Schuster, S
Glick, JH
Citation: Ph. Wiernik et al., Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: A long-term follow-up study of the Eastern Cooperative Oncology Group (E3481), LEUK LYMPH, 40(3-4), 2001, pp. 357-363
Authors:
Smalley, RV
Weller, E
Hawkins, MJ
Oken, MM
O'Connell, MJ
Haase-Statz, S
Borden, EC
Citation: Rv. Smalley et al., Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha 2a) plus an anthracycline-based induction regimen, LEUKEMIA, 15(7), 2001, pp. 1118-1122
Authors:
Fonseca, R
Oken, MM
Harrington, D
Bailey, RJ
Van Wier, SA
Henderson, KJ
Kay, NE
Van Ness, B
Greipp, PR
Dewald, GW
Citation: R. Fonseca et al., Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy, LEUKEMIA, 15(6), 2001, pp. 981-986
Authors:
Giantonio, BJ
Hochster, H
Blum, R
Wiernik, PH
Hudes, GR
Kirkwood, J
Trump, D
Oken, MM
Citation: Bj. Giantonio et al., Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: A report of two clinical trials of the Eastern Cooperative Oncology Group, INV NEW DR, 19(1), 2001, pp. 89-92
Authors:
Wallace, SR
Oken, MM
Lunetta, KL
Panoskaitsis-Mortari, A
Masellis, AM
Citation: Sr. Wallace et al., Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients, CANCER, 91(7), 2001, pp. 1219-1230
Authors:
Casassus, P
Gibson, J
Joshua, DE
Matthews, J
Diaz, JC
Gertz, MA
Kyle, R
Leong, T
Oken, MM
Fritz, E
Ludwig, H
Corrado, C
Lastiri, F
Peest, D
Grosbois, B
Vela-Ojeda, J
Avvisati, G
Mandelli, F
Petrucci, MT
Capnist, G
Child, JA
Drayson, MT
Dunn, J
MacLennan, I
Mellstedt, H
Osterborg, A
Rodjer, S
Turesson, I
Westin, J
Bergsagel, D
Browman, GP
Shustik, C
Zee, B
Hjorth, M
Holmberg, E
Rodjer, S
Turesson, I
Westin, J
Alison, R
Clarke, M
Elphinstone, P
Evans, V
Gray, R
Hicks, C
James, S
MacKinnon, L
Peto, R
Richards, S
Wheatley, K
Blade, J
Fontanillas, M
San Miguel, J
Aitchison, R
Newland, AC
Cunningham, D
Malpas, J
Powles, RL
Montuoro, A
Jacobson, J
Salmon, S
Citation: P. Casassus et al., Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients, BR J HAEM, 113(4), 2001, pp. 1020-1034
Authors:
Fonseca, R
Oken, MM
Greipp, PR
Citation: R. Fonseca et al., The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance, BLOOD, 98(4), 2001, pp. 1271-1272
Authors:
Kay, NE
Leong, TL
Bone, N
Vesole, DH
Greipp, PR
Van Ness, B
Oken, MM
Kyle, RA
Citation: Ne. Kay et al., Blood levels of immune cells predict survival in myeloma patients: resultsof an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosedmultiple myeloma patients, BLOOD, 98(1), 2001, pp. 23-28
Authors:
Lee, S
Tallman, MS
Oken, MM
Cassileth, PA
Bennett, JM
Wiernik, PH
Rowe, JM
Citation: S. Lee et al., Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia, LEUKEMIA, 14(8), 2000, pp. 1345-1348
Authors:
Robles, C
Kim, KM
Oken, MM
Bennett, JM
Letendre, L
Wiernik, PH
O'Connel, MJ
Cassileth, PA
Citation: C. Robles et al., Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483), LEUKEMIA, 14(8), 2000, pp. 1349-1353
Authors:
Hochster, HS
Oken, MM
Winter, JN
Gordon, LI
Raphael, BG
Bennett, JM
Cassileth, PA
Citation: Hs. Hochster et al., Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long-term follow-up - A report from the Eastern Cooperative Oncology Group, J CL ONCOL, 18(5), 2000, pp. 987-994
Authors:
Harris, JE
Ryan, L
Hoover, HC
Stuart, RK
Oken, MM
Benson, AB
Mansour, E
Haller, DG
Manola, J
Hanna, MG
Citation: Je. Harris et al., Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283, J CL ONCOL, 18(1), 2000, pp. 148-157
Authors:
Prorok, PC
Andriole, GL
Bresalier, RS
Buys, SS
Chia, D
Crawford, ED
Fogel, R
Gelmann, EP
Gilbert, F
Hasson, MA
Hayes, RB
Johnson, CC
Mandel, JS
Oberman, A
O'Brien, B
Oken, MM
Rafla, S
Reding, D
Rutt, W
Weissfeld, JL
Yokochi, L
Gohagan, JK
Citation: Pc. Prorok et al., Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, CONTR CL TR, 21(6), 2000, pp. 273S-309S
Authors:
Fonseca, R
Trendle, MC
Leong, T
Kyle, RA
Oken, MM
Kay, NE
Van Ness, B
Greipp, PR
Citation: R. Fonseca et al., Prognostic value of serum markers of bone metabolism in untreated multiplemyeloma patients, BR J HAEM, 109(1), 2000, pp. 24-29
Authors:
Tallman, MS
Neuberg, D
Bennett, JM
Francois, CJ
Paletta, E
Wiernik, PH
Dewald, G
Cassileth, PA
Oken, MM
Rowe, JM
Citation: Ms. Tallman et al., Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience, BLOOD, 96(7), 2000, pp. 2405-2411
Authors:
Wiernik, PH
Gordon, LI
Oken, MM
Harris, JE
O'Connell, MJ
Citation: Ph. Wiernik et al., Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group, LEUK LYMPH, 35(3-4), 1999, pp. 375-377
Authors:
Greipp, PR
Trendle, MC
Leong, T
Oken, MM
Kay, NE
Van Ness, B
Kyle, RA
Citation: Pr. Greipp et al., Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?, LEUK LYMPH, 35(1-2), 1999, pp. 83-89
Authors:
Gale, RP
Park, RE
Dubois, RW
Anderson, KC
Audeh, WM
Bergsagel, D
Jagannath, S
Kyle, RA
Oken, MM
Perlman, M
Rifkin, RM
Stone, MJ
Durie, B
Citation: Rp. Gale et al., Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow autotransplants in newly diagnosed multiple myeloma, LEUK LYMPH, 33(5-6), 1999, pp. 511-517
Authors:
Kay, N
Leong, T
Kyle, RA
Greipp, P
Van Ness, B
Bone, N
Oken, MM
Citation: N. Kay et al., Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myelomapatients, a study of the Eastern Cooperative Oncology Group (E9487), LEUK LYMPH, 33(1-2), 1999, pp. 127-133
Authors:
Trendle, MC
Leong, T
Kyle, RA
Katzmann, JA
Oken, MM
Kay, NE
Van Ness, BG
Greipp, PR
Citation: Mc. Trendle et al., Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (clg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486, AM J HEMAT, 61(4), 1999, pp. 232-237
Authors:
Oken, MM
Leong, T
Lenhard, RE
Greipp, PR
Kay, NE
Van Ness, B
Keimowitz, RM
Kyle, RA
Citation: Mm. Oken et al., The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma - Phase III Eastern Cooperative Oncology Group clinical trial EST 9486, CANCER, 86(6), 1999, pp. 957-968
Risultati:
1-22
|